Nathan Chen

No open positions remaining

58 year

Health Technology

Consumer Services

Profile

Nathan Chen worked as the Director of Regional Clinical Development at Boehringer Ingelheim Corp.
He then served as the Head of Immunology & Inflammation at GSK Plc from 2018 to 2020.
Currently, he is the Vice President of Regulatory Affairs at LianBio.
Mr. Chen holds graduate degrees from Purdue University, Rensselaer Polytechnic Institute, and the State University of New York at Albany.

Former positions of Nathan Chen

Companies	Position	End
LIANBIO	General Counsel	01/02/2023
GSK PLC	Corporate Officer/Principal	01/02/2020
Boehringer Ingelheim Corp. Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets health care products	Corporate Officer/Principal	-

See the detail of Nathan Chen's experience

Training of Nathan Chen

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Nathan Chen's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	6
GSK Plc GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products	Health Technology
Purdue University Purdue University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Rensselaer Polytechnic Institute Rensselaer Polytechnic Institute Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
State University of New York at Albany State University of New York at Albany Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Boehringer Ingelheim Corp. Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets health care products	Health Technology
LianBio LianBio BiotechnologyHealth Technology Operates as a biotechnology company focused on bringing paradigm-shifting medicines to patients	Health Technology

See company connections